| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | NADC3; SDCT2 |
| WB Predicted band size | 67 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC13A3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC13A3抗体的3篇参考文献示例(文献信息为虚构示例，仅供参考格式)：
1. **"SLC13A3 Expression in Renal Cell Carcinoma: A Prognostic Biomarker Study"**
*Authors: Smith A, et al.*
*摘要*：本研究通过免疫组化分析SLC13A3蛋白在肾透明细胞癌中的表达，发现其表达水平与患者生存率呈负相关，提示SLC13A3可能作为潜在治疗靶点。
2. **"Role of SLC13A3 in Neuronal Citrate Transport and Neurodegeneration"**
*Authors: Lee H, et al.*
*摘要*：利用SLC13A3特异性抗体在小鼠脑组织中发现该蛋白参与神经元线粒体柠檬酸转运，其功能异常可能与阿尔茨海默病病理相关。
3. **"Validation of a Novel Anti-SLC13A3 Antibody for Western Blot and Flow Cytometry"**
*Authors: Garcia R, et al.*
*摘要*：文章验证了一种新型SLC13A3多克隆抗体的特异性，证实其在多种细胞系中检测到约65 kDa的蛋白条带，并可用于流式细胞术定量分析。
4. **"SLC13A3 Modulates Macrophage Metabolism in Atherosclerosis"**
*Authors: Chen L, et al.*
*摘要*：通过抗体阻断实验发现，SLC13A3通过调控巨噬细胞内二羧酸代谢影响动脉粥样硬化斑块形成，为代谢干预提供新方向。
---
*注：以上文献为模拟内容，实际研究中请通过PubMed或Google Scholar以关键词"SLC13A3 antibody"+"specific research field"检索真实文献。*
The SLC13A3 antibody is a research tool targeting the solute carrier family 13 member 3 (SLC13A3) protein, a sodium-dependent dicarboxylate transporter. SLC13A3 facilitates cellular uptake of dicarboxylates like succinate, citrate, and α-ketoglutarate, which are critical intermediates in metabolic pathways such as the tricarboxylic acid (TCA) cycle. Primarily expressed in the kidney, liver, and placenta, SLC13A3 regulates energy homeostasis, pH balance, and renal reabsorption processes. Its role extends to mitochondrial function, gluconeogenesis, and lipid synthesis.
Antibodies against SLC13A3 are used to study its expression, localization, and function in physiological and pathological contexts. Research links SLC13A3 dysregulation to diseases including renal disorders, metabolic syndromes, and cancers. For instance, reduced SLC13A3 expression has been observed in renal cell carcinoma, while overexpression may influence cancer cell metabolism. The antibody aids in detecting protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence, providing insights into tissue-specific distribution and disease mechanisms.
Commercial SLC13A3 antibodies are typically developed in rabbits or mice, validated for specificity across human, mouse, or rat samples. Understanding SLC13A3's role through antibody-based studies could uncover therapeutic targets for metabolic diseases or cancer, highlighting its potential in translational research.
×
